EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts

Mara Memoli iD, Stefania Leone, Vincenzo Fotticchia iD, Simona Avilia, Novella Pugliese, Catello Califano, Maria Di Perna, Danilo De Novellis iD, Antonella Malandrini, Bianca Serio, Camilla Frieri iD, Giuseppe Gaeta und 12 weitere

Hematological Oncology · 2026-11 · 44 (6)

DOI: 10.1002/hon.70281 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Hematological Oncology, online erschienen am 06.11.2026. Verfasst von Mara Memoli und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Hematology Division, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Hematinics, Myelodysplastic Syndromes, Anemia, Sideroblastic, Blood Cell Count. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long‐term real‐world data on Luspatercept (Luspa) in lower‐risk myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and transfusion‐dependent anemia (RBC‐TD) who are refractory or ineligible to erythropoiesis‐stimulating agents (ESAs) remain limited. Despite evidence of efficacy from clinical trials and real‐world studies, long‐term data in routine clinical practice are scarce, particularly regarding its effects on non‐erythroid lineages. Furthermore, there is currently no consensus on the total duration of treatment, especially in non‐responding cases. Thus, we analyzed 48 patients with low‐risk MDS‐RS treated with Luspa for ESA‐refractory RBC‐TD. Response was assessed at 6 months, 1 year, and 2 years according to International Working Group (IWG) 2018 criteria. At 6 months, 23/42 (54.8%) and 15/42 (35.7%) patients reached a response and transfusion independence, respectively. At 1 year, 16/30 (53.3%) patients showed a response, including 12 who already responded at 6 months. At 2 years, 10/20 (50%) patients maintained response and 2/20 (10%) were de novo responders. Treatment was well tolerated, with no significant adverse events reported; 21 (43.8%) patients discontinued Luspa, principally due to lack of response. After a median follow‐up of 29.8 months (95% CI: 24.4–35.2), 6‐month responders had longer overall survival in a landmark analysis. Exploratory analyses identified associations of 6‐month response with additional somatic mutations and the SF3B1 hotspot mutation, the latter retained in the multivariable model; monocyte count was associated with 2‐year response. Neutrophil counts significantly increased at 1 year compared with baseline, while platelet counts remained stable. Intriguingly, monocytes were increased at the three time points compared to baseline. Specifically, long‐term responders presented higher levels of neutrophils and monocytes, as well decreased level of LDH, compared with non‐responders. Responses were observed during long‐term treatment, mainly in patients who had responded at earlier assessments. Decreasing evaluable sample sizes and the retrospective design limit interpretation. Associations with survival and non‐erythroid blood counts require confirmation and should not be interpreted as causal effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HematinicsMyelodysplastic SyndromesAnemia, SideroblasticBlood Cell CountTreatment OutcomeHumansMaleFemaleAgedAged, 80 and overBlood TransfusionRetrospective StudiesImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsActivin Receptors, Type II

Stichwörter der Autor:innen

Luspatercepterythroid responsemyelodysplastic syndromes (MDS)non erythroid effectstransfusion dependence

Substanzen

luspaterceptHematinicsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsActivin Receptors, Type II

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, Hematology Division, University of Naples Federico II, Naples, Italy.
  • Hematopoietic Stem Cell Transplantation Unit, Azienda Ospedaliera A. Cardarelli, Naples, Italy.
  • Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Division of Onco-Hematology, Plesso Ospedaliero Andrea Tortora, Pagani, Italy.
  • Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Baronissi, Italy.
  • Hematology and Transplant Center, University Hospital San Giovanni Di Dio e Ruggi d'Aragona, Salerno, Italy.

ORCID-Profile: Mara Memoli, Vincenzo Fotticchia, Danilo De Novellis, Camilla Frieri, Giuseppe Cerciello, Mario Annunziata, Giorgia Battipaglia, Marco Picardi, Francesco Grimaldi, Fabrizio Pane

Zitieren

APA

Memoli, M., Leone, S., Fotticchia, V., Avilia, S., Pugliese, N., Califano, C., Di Perna, M., De Novellis, D., Malandrini, A., Serio, B., Frieri, C., Gaeta, G., Masucci, C., D'Ambrosio, A., Della Cioppa, P., Cerciello, G., Izzo, T., Annunziata, M., Maddaloni, A., …, & Pane, F. (2026). Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts. Hematological Oncology, 44(6). https://doi.org/10.1002/hon.70281

Vancouver

Memoli M, Leone S, Fotticchia V, Avilia S, Pugliese N, Califano C, et al. Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts. Hematological Oncology. 2026;44(6). doi:10.1002/hon.70281

BibTeX
@article{Memoli2026,
  author = {Memoli, Mara and Leone, Stefania and Fotticchia, Vincenzo and Avilia, Simona and Pugliese, Novella and Califano, Catello and Di Perna, Maria and De Novellis, Danilo and Malandrini, Antonella and Serio, Bianca and Frieri, Camilla and Gaeta, Giuseppe and Masucci, Chiara and D'Ambrosio, Alessandro and Della Cioppa, Paola and Cerciello, Giuseppe and Izzo, Tiziana and Annunziata, Mario and Maddaloni, Annamaria and Quagliano, Cono and Battipaglia, Giorgia and Picardi, Marco and Grimaldi, Francesco and Pane, Fabrizio},
  title = {Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {6},
  doi = {10.1002/hon.70281}
}
Kostenlos starten →